Trillium Therapeutics Inc.'s Anti-CD47 Oncology Program Highlighted in Prestigious Journal
9/7/2012 10:17:48 AM
More...
|
Trillium Therapeutics Inc. Provides Update on Anti-CD47 Cancer Program
4/5/2012 8:52:47 AM
More...
|
First Patient Treated in Trillium Therapeutics Inc.'s Interstitial Cystitis/Bladder Pain Syndrome Clinical Trial
3/28/2012 10:50:43 AM
More...
|
Trillium Therapeutics Inc. to Commence Clinical Testing of TTI-1612 in Patients with Interstitial Cystitis/Bladder Pain Syndrome
12/15/2011 11:05:12 AM
More...
|
Trillium Therapeutics Inc. Raises Funds to Advance Urology Program Into Clinical Trials
5/12/2011 7:17:10 AM
More...
|
Trillium Therapeutics Inc.'s Cancer Stem Cell Program to be Highlighted at American Society of Hematology
12/2/2010 1:25:14 PM
More...
|
Trillium Therapeutics Inc. Expands Immunology Pipeline and Enters Stem Cell Field Through In-licensing of Two New Programs
3/11/2010 9:05:24 AM
More...
|
Trillium Therapeutics Inc. Adds Industry Veteran Dr. Mike Gresser to its Board of Directors
1/28/2010 9:22:38 AM
More...
|
Trillium Therapeutics Inc. and Biogen Idec, Inc. (Massachusetts) (BIIB) Enter into Global License Agreement
1/12/2010 8:39:47 AM
More...
|
Trillium Therapeutics Inc. Strengthens its Board of Directors
11/5/2008 2:34:35 PM
More...
|
|